Engineering trustworthy closed-loop bioelectronic systems for cardiovascular disease
Establishing closed-loop clinical management for cardiovascular disease (CVD) remains more challenging than in many other medical domains. The cardiovascular system couples electrical, mechanical, biochemical, and neurohumoral signals across rapid, tightly interconnected timescales, creating a high-risk environment in which uncertainty can rapidly propagate into therapeutic error. CVD therapy must distinguish pathological states from normal physiological variations in real time, setting it apart from other mature closed-loop systems (e.g., insulin delivery) that manage a single variable over minutes (Figure 1A). Cardiovascular closed-loop therapy must be conceptualized not as integrated hardware but as a trustworthy, life-saving control system that converts uncertain physiological information into actionable, clinically relevant interventions within a safe operating range. The next frontier is no longer integration alone but how to engineer reliability, interpretability, and adaptive decision intelligence into the therapeutic loop.
Pioneering prototypes and the path toward integration
Recent breakthroughs in prototype bioelectronics have established the feasibility of integrated sophisticated sensing with localized therapeutic action. Lee et al. developed a dual-component platform of ultraflexible nanoelectronics1 to monitor the integration of transplanted human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) within host cardiac tissues (Figure 1B). This research offers a long-term, cell-resolved observation window into the electrophysiological mechanisms of arrhythmogenesis. By revealing how these engineered tissues interact with the native myocardium, such platforms provide the essential diagnostic infrastructure required to understand and eventually mitigate post-transplantation risks. While these systems focus on the observational dimension of regenerative medicine, they establish the necessary technological foundation for future architectures that might incorporate active rhythm-management capabilities.
Zou et al. demonstrated a closed-loop bioelectronic patch for intelligent blood-pressure management (Figure 1B).2 In this system, nitric oxide release or termination was triggered by the elevation and normalization of blood pressures, allowing immediate therapeutic output in response to physiological input. This represents a step in moving closed-loop cardiovascular control from conceptual possibility to tangible engineering reality, illustrating the translational potential of wearable and unobtrusive therapeutic devices. The decision logic here still relies on a single physiological threshold. It cannot describe comprehensive cardiovascular dynamics. An elevation in blood pressure during intense activity represents a healthy adaptive response, unlike a hypertensive surge at rest.
These prototypes demonstrate that cardiovascular closed-loop systems are no longer speculative: high-fidelity sensing can be coupled to localized therapeutic action. The next challenge is not further integration but the design of controllers that remain reliable under context-dependent cardiovascular dynamics. This challenge involves three tightly coupled layers: the tissue-device interface, the energy-computation architecture, and the decision intelligence that governs therapy.
